A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

American Journal of Hematology

Volumn 86, Issue 7, 2011, Pages 573-578

  Ghobrial, Irene M ^a   Munshi, Nikhil C ^a   Harris, Brianna N ^a   Shi, Peipei ^b   Porter, Nichole M ^c   Schlossman, Robert L ^a   Laubach, Jacob P ^a   Anderson, Kenneth C ^a   Desaiah, Durisala ^b   Myrand, Scott P ^b   Wooldridge, James E ^b   Richardson, Paul G ^a   Abonour, Rafat ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DRUG METABOLITE; ENZASTAURIN;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ANXIETY; ARTICLE; BACKACHE; BONE PAIN; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPONATREMIA; KIDNEY DISEASE; KIDNEY TUBULE NECROSIS; LEUKOPENIA; LOADING DRUG DOSE; MALE; MOOD CHANGE; MULTICENTER STUDY; MULTIPLE MYELOMA; NAUSEA; NEURALGIA; NEUROPATHY; NEUTROPENIA; PAIN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; RELAPSE; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; TIME FACTORS;

EID: 79959361375     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22048     Document Type: Article

References (16)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009; 15: 5250-5257.
3. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood 2007; 110: 3557-3560.
4. Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79: 867-874.
5. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
6. Dawson MA, Opat SS, Taouk Y, et al. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma. Clin Cancer Res 2009; 15: 714-722.
7. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005; 65: 7462-7469.
8. Neri A, Marmiroli S, Tassone P, et al. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma 2008; 49: 1374-1383.
9. Podar K, Raab MS, Zhang J, et al. Targeting PKC in multiple myeloma: In vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2007; 109: 1669-1677.
10. Ghobrial IM, Dispenzieri A, Bundy KL, et al. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant 2003; 32: 587-592.
11. Podar K, Raab MS, Chauhan D, Anderson KC. The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs 2007; 16: 1693-1707.
12. Crowley J, Hoering A, Ankerst D, editors. Handbook of Statistics in Clinical Oncology, 2nd ed. Boca Ratox: CKC Press; 2005. 640 p.
13. National Cancer Institute: Cancer Therapy Evaluation Program [Internet]. Common Terminology Criteria for Adverse Events, version 3.0. August 9, 2006 [cited on 29 November 2010]. Available from:.
14. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
15. Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: Final time-to-event results from the SUMMIT trial. Cancer 2006; 106: 1316-1319.
16. Velcade® [bortezomib] label [Internet; cited on 11 October 2010]. pp 20-21. Available from:.